During the recent session, Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)’s traded shares were 1.93 million, with the beta value of the company hitting 0.38. At the last check today, the stock’s price was $504.00, reflecting an intraday loss of -16.75% or -$101.39. The 52-week high for the REGN share is $1211.20, that puts it down -140.32 from that peak though still a striking -3.27% loss since the share price plummeted to a 52-week low of $520.50. The company’s market capitalization is $54.41B, and the average intraday trading volume over the past 10 days was 0.93 million shares, and the average trade volume was 1.15 million shares over the past three months.
Regeneron Pharmaceuticals, Inc (REGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.52. REGN has a Sell rating from 0 analyst(s) out of 22 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 21 recommend a Buy rating for it.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) trade information
Regeneron Pharmaceuticals, Inc (REGN) registered a -16.75% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -16.75% in intraday trading to $504.00, hitting a weekly high. The stock’s 5-day price performance is -15.56%, and it has moved by -15.83% in 30 days. Based on these gigs, the overall price performance for the year is -48.21%. The short interest in Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is 2.8 million shares and it means that shorts have 2.07 day(s) to cover.
The consensus price target of analysts on Wall Street is $850, which implies an increase of 40.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $695 and $903 respectively. As a result, REGN is trading at a discount of -79.17% off the target high and -37.9% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.74%. While earnings are projected to return -21.65% in 2025, the next five years will return 1.93% per annum.
REGN Dividends
Regeneron Pharmaceuticals, Inc is due to release its next quarterly earnings on 2025-Apr-28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Regeneron Pharmaceuticals, Inc is 1.76, with the dividend yield indicating at 0.35 percent, continuing the trend of increasing dividends in recent years.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN)’s Major holders
Regeneron Pharmaceuticals, Inc insiders own 1.90% of total outstanding shares while institutional holders control 92.08%, with the float percentage being 93.86%. FMR LLC is the largest shareholder of the company, while 1858.0 institutions own stock in it. As of 2024-06-30, the company held over 10.65 million shares (or 9.8515% of all shares), a total value of $11.19 billion in shares.
The next largest institutional holding, with 8.99 million shares, is of VANGUARD GROUP INC’s that is approximately 8.32% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.45 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Regeneron Pharmaceuticals, Inc (REGN) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 3.4 shares. This amounts to just over 3.18 percent of the company’s overall shares, with a $1.69 billion market value. The same data shows that the other fund manager holds slightly less at 2.92, or about 2.73% of the stock, which is worth about $1.46 billion.
